Narrative Review: Reversible Cerebral Vasoconstriction Syndromes
- L. Calabrese, D. Dodick, T. Schwedt, A. Singhal
- MedicineAnnals of Internal Medicine
- 2 January 2007
This narrative review, by specialists in the field of rheumatology, headache, and stroke, will outline the cause and pathophysiology, symptoms and signs, diagnosis, treatment, and prognosis of RCVS and areas of uncertainty.
New Appendix Criteria Open for a Broader Concept of Chronic Migraine
- J. Olesen, M. Bousser, T. Steiner
- MedicineCephalalgia
- 1 June 2006
The International Headache Classification Committee has worked out the more inclusive criteria for CM and MOH and it is now recommended that the MOH diagnosis should no longer request improvement after discontinuation of medication overuse but should be given to patients if they have a primary headache plus ongoing medication over use.
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program
(Headache 2010;50:921‐936)
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
- B. Weinshenker, P. O'brien, Moses Rodriguez
- Medicine, PsychologyAnnals of Neurology
- 1 December 1999
Plasma exchange leads to functionally important neurological recovery in an important proportion of severely disabled patients with acute attacks of idiopathic inflammatory demyelinating disease, and was sustained on follow‐up.
A self-administered screener for migraine in primary care
- R. Lipton, D. Dodick, W. Harrison
- Medicine, PsychologyNeurology
- 12 August 2003
The three-item ID Migraine™ migraine screener was found to be a valid and reliable screening instrument for migraine headaches and its ease of use and operating characteristics suggest that it could significantly improve migraine recognition in primary care.
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
As a preventive treatment of episodic migraine, erenumab at a dosage of 70 mg monthly significantly reduced migraine frequency and acute migraine-specific medication use.
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
- J. Saper, D. Dodick, S. Silberstein, S. McCarville, Mark Sun, P. Goadsby
- Medicine, PsychologyCephalalgia
- 1 February 2011
The results of this feasibility study offer promise and should prompt further controlled studies of occipital nerve stimulation (ONS) in CM.
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled,…
- T. Ho, M. Ferrari, P. Winner
- Medicine, PsychologyThe Lancet
- 20 December 2008
Fremanezumab for the Preventive Treatment of Chronic Migraine
- S. Silberstein, D. Dodick, E. Aycardi
- MedicineNew England Journal of Medicine
- 24 November 2017
Fremanezumab as a preventive treatment for chronic migraine resulted in a lower frequency of headache than placebo in this 12‐week trial, and the long‐term durability and safety of fremanzumab require further study.
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults
- S. Silberstein, S. Holland, F. Freitag, D. Dodick, C. Argoff, E. Ashman
- Medicine, PsychologyNeurology
- 24 April 2012
Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity.
...
...